Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avalo Therapeutics, Inc.
Report date May 15, 2018 · Filed October 18, 2018
Jointly reported with Fremantle, LLC
Section 16 reporting ended · disclosed 2018-10-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2018 Filed Oct 18, 2018 21:10 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,270 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001567619-18-004305 · doc1.xml · derivative · entry 3 Jones Randal · CIK 0001723453 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,270 shares Expires 2018-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2018 Filed Oct 18, 2018 21:10 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | SaleCommon Stock | 1,270 | $3.98 | $5,054.60 |
DisclosureSEC source: 0001567619-18-004305 · doc1.xml · nonDerivative · entry 2 Jones Randal · CIK 0001723453 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 13, 2018 Filed Oct 18, 2018 21:10 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | Exercise / conversionCommon Stock | 1,270 | $3.20 | $4,064.00 |
DisclosureSEC source: 0001567619-18-004305 · doc1.xml · nonDerivative · entry 1 Jones Randal · CIK 0001723453 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 21:27 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,012 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001562180-18-003169 · primarydocument.xml · derivative · entry 1 Jones Randal · CIK 0001723453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 Underlying: Common Stock · 1,012 shares Expires 2028-06-29 Read SEC document |
| March 31, 2018 Filed Apr 4, 2018 18:34 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,056 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001562180-18-001828 · primarydocument.xml · derivative · entry 1 Jones Randal · CIK 0001723453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,056 Underlying: Common Stock · 2,056 shares Expires 2028-03-30 Read SEC document |
| December 31, 2017 Filed Jan 4, 2018 15:14 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,270 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001562180-18-000176 · primarydocument.xml · derivative · entry 1 Jones Randal · CIK 0001723453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270 Underlying: Common Stock · 1,270 shares Expires 2027-12-30 Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:04 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (right to buy) · Derivative | 16,714 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001104659-17-069923 · a4.xml · derivative · entry 2 Jones Randal · CIK 0001723453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,714 Underlying: Common Stock · 16,714 shares Expires 2027-11-17 F2 · derivative.exercise_date: The grant shall vest one-third on each of the first, second and third anniversaries of the date of grant, provided Mr. Jones is then a director of the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.